NanoRNP Overcomes Tumor Heterogeneity in Cancer Treatment
- 8 October 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 19 (11) , 7662-7672
Abstract
Tumor heterogeneity has been one of the most important factors leading to the failure of conventional cancer therapies due to the accumulation of genetically distinct tumor-cell subpopulations during tumor development process. Due to the diversity of genetic mutations during tumor growth, combining use of multiple drugs have only achieved limited success in combating heterogeneous tumors. Herein, we report a novel anti-tumor strategy that effectively addresses tumor heterogeneity by using a CRISPR/Cas9-based nanoRNP carrying a combination of sgRNAs. Such nanoRNP is synthesized from Cas9 ribonucleoprotein, any combinations of required sgRNAs, and a rationally designed responsive polymer that endows nanoRNP with high circulating stability, enhanced tumor accumulation, and the efficient gene editing in targeted tumor cells eventually. By carrying a combination of sgRNAs that targets STAT3 and RUNX1, the nanoRNP exhibited efficient gene expression disruptions on a heterogeneous tumor model with two subsets of cells whose proliferations were sensitive to the reduced expression of STAT3 and RUNX1 respectively, leading to the effective growth inhibition of the heterogeneous tumor. Considering the close relationship between tumor heterogeneity and cancer progression, resistance to therapy, and recurrences, nanoRNP provides a feasible strategy to overcome tumor heterogeneity in the development of more advanced cancer therapy against malignant tumors.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2018YFA0209700)
- Ministry of Education of the People's Republic of China (ZB19100123, ZB16008705, 63191110)
- Tianjin Municipal Science and Technology Committee (17JCZDJC36500)
- National Natural Science Foundation of China (21620102005, 81671169, 51673100, 51503122)
- PCSIRT (IRT1257)
- Thousand Talents Program for Young Professionals
- Special Construction Innovation Funded Project for Community in Beijing, Tianjin and Hebei of China (18247792D)
This publication has 43 references indexed in Scilit:
- Intratumor heterogeneity alters most effective drugs in designed combinationsProceedings of the National Academy of Sciences, 2014
- Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination TherapyCancer Discovery, 2014
- Tumour heterogeneity in the clinicNature, 2013
- The causes and consequences of genetic heterogeneity in cancer evolutionNature, 2013
- Tumor heterogeneity and its implication for drug deliveryJournal of Controlled Release, 2012
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic LeukemiaScience, 2008
- TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENTAnnual Review of Pathology: Mechanisms of Disease, 2006
- A mathematical model of drug resistance: Heterogeneous tumorsMathematical Biosciences, 1998
- A stochastic model for the origin and treatment of tumors containing drug-resistant cellsBulletin of Mathematical Biology, 1986